although
drug
develop
strongli
contribut
find
superior
therapeut
efficaci
still
space
need
improv
addit
classic
drug
screen
small
molecul
innov
modern
approach
biotechnolog
genom
research
contribut
new
therapeut
possibl
area
vaccin
develop
gene
immunotherapi
context
rnabas
therapeut
becom
interest
altern
rnabas
drug
classifi
mechan
action
includ
antisens
approach
inhibit
mrna
translat
gene
silenc
rna
interfer
catalyt
activ
ribozym
protein
bind
rna
molecul
aptam
diagnost
therapeut
applic
context
lipidencapsul
nanoparticl
contain
doublestrand
small
interf
rna
sirna
appli
bind
transthyretin
ttr
mrna
caus
degrad
ttr
deposit
present
patient
hereditari
ttrmediat
amyloidosi
novel
rna
interferencebas
drug
patisiran
recent
approv
us
europ
singl
intraven
infus
recent
messeng
rna
mrna
gener
vitro
transcript
becom
attract
target
drug
vaccin
develop
two
approach
mrnabas
drug
taken
base
ex
vivo
transfect
cell
patient
direct
mrna
administr
context
preclin
clinic
studi
conduct
area
cancer
immunotherapi
vaccin
develop
infecti
diseas
protein
replac
gene
edit
relat
mrnabas
drug
approach
employ
selfrepl
rna
virus
provid
interest
attract
altern
enhanc
deliveri
efficaci
uniqu
featur
highrat
cytoplasm
replic
combin
extrem
transgen
express
made
rna
virus
system
choic
rna
therapeut
review
selfrepl
vector
describ
applic
preclin
studi
clinic
trial
discuss
alphavirus
belong
famili
togaviridia
common
alphavirus
engin
express
vector
base
semliki
forest
viru
sfv
sindbi
viru
sin
venezuelan
equin
enceph
viru
vee
alphaviru
genom
consist
four
nonstructur
gene
respons
rna
selfrepl
gene
capsid
envelop
protein
figur
engin
alphaviru
vector
gener
replicationdefici
profici
recombin
particl
suitabl
transgen
express
cell
line
vivo
introduct
cmv
promot
upstream
nsp
gene
allow
direct
transfect
plasmid
dna
selfrepl
rna
capac
due
design
altern
alphaviru
vector
possibl
conduct
studi
nake
rna
replicon
recombin
viral
particl
layer
vector
similar
way
alphavirus
flavivirus
also
possess
ssrna
genom
posit
polar
instanc
base
kunjin
viru
kun
vector
engin
deliveri
rna
recombin
particl
dna
plasmid
figur
contrast
alphavirus
gene
interest
insert
downstream
nonstructur
gene
first
nucleotid
core
protein
last
codon
envelop
protein
frame
viral
polyprotein
although
recombin
protein
interest
initi
part
larg
polyprotein
process
individu
protein
remain
flank
region
remov
proteas
sequenc
introduc
kun
vector
support
viru
product
packag
cell
line
engin
kun
express
vector
base
flavivirus
west
nile
viru
yellow
fever
viru
dengu
viru
tickborn
enceph
viru
gener
neg
polar
mv
ssrna
genom
requir
engin
packag
system
rescu
replic
mv
clone
dna
express
construct
rescu
recombin
mv
establish
helper
cell
line
revers
genet
express
vector
carri
mv
structur
protein
downstream
rna
polymeras
promot
design
introduct
foreign
gene
phosphoprotein
p
matrix
protein
altern
hemagglutinin
ha
larg
protein
l
figur
gener
recombin
mv
particl
helper
cell
line
transfect
recombin
mv
construct
plasmid
contain
mv
polymeras
l
gene
recombin
mv
harvest
three
day
transfect
reach
cytopath
effect
rabi
viru
rabv
figur
vesicular
stomat
viru
vsv
subject
express
vector
engin
mv
neg
ssrna
genom
rhabdovirus
requir
applic
revers
genet
base
recombin
vaccinia
viru
vector
establish
effici
transgen
express
howev
vsv
n
p
l
gene
insert
downstream
promot
intern
ribosom
entri
site
ire
effici
recoveri
vsv
particl
obtain
transfect
dna
vaccinia
virusfre
system
similarli
rabv
viru
vector
engin
gene
interest
introduc
rabv
n
p
gene
moreov
recoveri
rabv
clone
cdna
achiev
vaccinia
virusfre
revers
genet
system
anoth
approach
chimer
viruslik
particl
vlp
sfv
rna
replicon
encapsul
vsv
glycoprotein
vsvg
engin
provid
addit
biosafeti
selfrepl
rna
viru
vector
subject
numer
preclin
immun
studi
target
infecti
diseas
tabl
context
dengu
viru
target
immun
mv
express
domain
iii
dengu
viru
envelop
protein
elicit
robust
neutral
antibodi
mvsuscept
mice
moreov
immun
mv
display
domain
iii
gener
neutral
antibodi
also
provid
protect
four
dengu
viru
serotyp
mice
similarli
much
attent
paid
vaccin
develop
ebola
viru
instanc
express
ebola
glycoprotein
gp
kun
vsv
vector
provid
protect
ebola
viru
challeng
nonhuman
primat
moreov
immun
veenp
render
mice
resist
ebola
infect
mice
anoth
studi
immun
vee
vector
express
ebola
gp
nucleoprotein
np
evalu
balbc
mice
two
strain
guinea
pig
singl
administr
veegp
vlp
combin
veegp
np
vlp
provid
protect
mice
guinea
pig
contrast
veenp
vlp
alon
protect
mice
guinea
pig
recent
studi
applic
dnarna
layer
selfrepl
sfv
vector
coexpress
ebola
gp
elicit
bind
neutral
antibodi
immunogen
superior
modifi
vaccinia
viru
ankara
mva
vaccin
could
enhanc
mva
boost
relat
hepat
b
viru
hbv
mv
vector
express
hepat
b
surfac
antigen
hbsag
demonstr
elicit
humor
respons
mvsuscept
genet
modifi
mice
rhesu
monkey
immun
mvhbsag
remain
healthi
anoth
studi
sfv
rna
replicon
express
vsv
g
gener
viruslik
vesicl
vlv
engin
carri
hbv
middl
surfac
envelop
glycoprotein
mhb
immun
mice
result
cell
respons
show
higher
magnitud
broader
specif
comparison
immun
recombin
protein
dna
singl
administr
mhbvlv
protect
mice
hbv
challeng
contrast
immun
sfv
vlv
express
hbv
core
protein
hbcag
produc
cell
respons
hbv
protect
surprisingli
human
immunodefici
viru
hiv
subject
vaccin
develop
appli
selfrepl
rna
vector
context
sfv
vector
express
hiv
env
gene
administ
plasmid
dna
mice
compar
recombin
env
glycoprotein
vaccin
humor
immun
respons
envelop
strongest
sfv
recombin
particl
compar
hiv
env
vaccin
test
anoth
studi
sfv
rna
express
env
protein
administ
intramuscularli
mice
gener
envspecif
antibodi
respons
four
five
mice
recent
mice
immun
sfv
vector
express
hiv
envgagpolrt
gene
either
individu
combin
elicit
signific
cell
respons
immun
respons
stronger
sfv
vrp
rna
replicon
dna
base
sfv
vector
express
env
gagpolnef
fusion
protein
also
subject
immun
follow
heterolog
boost
mva
andor
hiv
protein
formul
glycopyranosyl
lipid
glaaf
adjuv
immun
sfv
dna
induc
lower
hivspecif
cell
igg
respons
immun
sfvdna
howev
immun
respons
two
dose
similarli
effici
boost
perform
mva
hiv
furthermor
singl
low
dose
sfvdna
elicit
superior
immun
respons
compar
mva
protein
antigen
alon
much
attent
also
paid
vaccin
develop
influenza
viru
instanc
sfvbase
express
influenza
viru
nucleoprotein
np
elicit
system
immun
respons
intravascular
inject
mucos
immun
respons
intranas
administr
moreov
vee
particl
carri
hemagglutinin
ha
gene
hong
kong
influenza
isol
administ
chicken
embryo
young
chick
bird
challeng
lethal
dose
influenza
viru
inocul
ovo
day
age
provid
partial
protect
singl
week
result
complet
protect
similarli
recombin
sfv
particl
express
influenza
ha
np
provid
protect
challeng
influenza
viru
recent
comparison
synthet
mrna
selfrepl
vee
rna
express
influenza
ha
equival
protect
obtain
strategi
howev
selfrepl
rna
need
wherea
mrna
materi
requir
protect
observ
influenza
strain
b
massachusett
moreov
trival
formul
protect
sequenti
challeng
lassa
virus
also
subject
vaccin
develop
instanc
vsv
vector
express
lassa
viru
glycoprotein
demonstr
protect
guinea
pig
challeng
lassa
viru
origin
liberia
mali
nigeria
moreov
complet
protect
also
obtain
macaqu
challeng
lethal
dose
liberian
lassa
viru
isol
furthermor
bicistron
vee
vector
express
lassa
viru
glycoprotein
distantli
relat
clade
iv
individu
subgenom
promot
elicit
immun
respons
vaccin
mice
provid
protect
lassa
viru
challeng
interestingli
vaccin
base
lassa
viru
replicon
particl
devoid
essenti
lassa
viru
glycoprotein
gene
evalu
guinea
pig
model
approach
nonspread
lassa
viru
replicon
particl
produc
vero
cell
administ
guinea
pig
show
protect
fever
weight
loss
lethal
relat
middl
east
respiratori
syndrom
coronaviru
merscov
replic
compet
mv
use
express
fulllength
spike
glycoprotein
merss
truncat
solubl
variant
merssol
vaccin
candid
induc
robust
level
mv
merscovneutr
antibodi
primeboost
regimen
mice
furthermor
immun
respons
render
protect
capac
vaccin
mice
likewis
vee
replicon
particl
appli
vaccin
develop
sever
acut
respiratori
syndrom
coronaviru
sarscov
studi
demonstr
age
balbc
mice
vaccin
attenu
vee
vrp
fail
protect
sarscov
diseas
wildtyp
vee
vrp
gave
protect
sarscov
vee
vlp
appli
express
human
metapneumoviru
hmpv
respiratori
syncyti
viru
hrsv
fusion
f
protein
immun
african
green
monkey
gener
rsv
mpv
fspecif
antibodi
respect
moreov
lower
level
viral
genom
detect
nasopharyng
bronchoalveolar
lavag
fluid
anoth
studi
vee
vector
employ
vaccin
develop
focu
replicon
deliveri
context
vee
vlp
compar
nake
rna
rna
encapsul
lipid
nanoparticl
lnp
report
gene
express
mice
reveal
higher
level
rnalnp
deliveri
compar
nake
rna
intramuscular
administr
despit
administr
rnalnp
compar
rna
moreov
comparison
vivo
express
show
highest
level
plasmid
dna
follow
rnalnp
lowest
express
level
detect
rna
deliveri
contrast
rsvf
specif
antibodi
titer
similar
iu
vee
particl
rnalnp
wherea
nake
rna
gener
lower
titer
electropor
dna
provid
similar
antibodi
respons
rnalnp
deliveri
dnalnp
ineffici
gener
lower
titer
rnalnp
sever
studi
carri
simian
immunodefici
viru
siv
vaccin
base
selfrepl
rna
virus
context
four
differ
kunbas
sivmac
gag
vaccin
evalu
mice
comparison
modifi
gagpol
gene
construct
superior
wildtyp
gag
rnaoptim
gag
codonoptim
gag
immun
respons
induct
protect
siv
challeng
mice
anoth
studi
sfv
mva
express
env
gagpol
nef
rev
tat
evalu
macaqu
sfvsivmac
mvasivmac
immun
alon
elicit
low
undetect
cytotox
cell
respons
howev
two
immun
sfvsivmac
follow
boost
mvasivmac
increas
antibodi
high
cell
respons
howev
protect
siv
challeng
achiev
support
vaccin
develop
gene
silenc
appli
extent
context
microrna
mirna
sequenc
target
rna
replic
introduc
vee
helper
vector
use
replicon
particl
product
cellular
mirna
downregul
replicon
rna
replic
vivo
effici
vee
particl
product
restor
addit
mirnaspecif
inhibitor
contribut
futur
therapeut
applic
moreov
inhibit
vee
replic
achiev
bhk
cell
introduct
five
artifici
mirna
target
rnadepend
rna
polymeras
rdrp
similar
viral
diseas
numer
preclin
studi
carri
cancer
prevent
therapi
tabl
context
retarget
mv
vector
carri
signal
lymphocyt
activ
molecul
slam
incorpor
ha
protein
combin
display
singlechain
antibodi
epiderm
growth
factor
receptor
egfr
c
terminu
ha
demonstr
retarget
mv
present
potent
antitumor
activ
egfr
egfrviii
primari
glioblastoma
cell
line
moreov
intratumor
administr
glioblastoma
xenograft
provid
tumor
regress
signific
prolong
surviv
likewis
sfv
vector
express
endostatin
compar
vivo
administr
sfvlacz
retroviru
gcsapendostatin
mice
bear
brain
tumor
sfvendostatin
provid
signific
inhibit
tumor
growth
furthermor
contrast
sfvlacz
gcsapendostatin
treatment
sfvendostatin
gener
mark
reduct
intratumor
vascular
addit
higher
endostatin
serum
level
observ
sfvendostatin
gcsapendostatin
indic
inhibit
angiogenesi
could
provid
new
mean
brain
tumor
therapi
anoth
approach
neurontarget
sequenc
introduc
strain
display
increas
oncolyt
potenc
murin
astrocytoma
cell
human
glioblastoma
cell
line
singl
intraperiton
inject
show
viru
replic
tumor
signific
tumor
growth
inhibit
improv
surviv
mice
implant
orthotop
glioma
relat
breast
cancer
edmonston
mv
strain
engin
express
carcinoembryon
antigen
cea
mvcea
vector
show
signific
cytopath
effect
sever
breast
cancer
cell
line
intraven
administr
balbc
nude
mice
xenograft
result
statist
signific
delay
tumor
growth
prolong
surviv
anoth
approach
sin
adenoviru
ad
vector
express
rat
gene
subject
immun
studi
mice
inhibit
tumor
cell
detect
anim
immun
sin
ad
prior
tumor
challeng
contrast
vaccin
two
day
tumor
challeng
ineffect
sin
ad
hand
sinneu
immun
follow
adneu
vaccin
primeboost
protocol
surviv
rate
significantli
improv
mice
intraven
challeng
tumor
cell
suscept
dendrit
cell
dc
veeencourag
studi
therapeut
efficaci
anim
model
immun
dc
transduc
vee
recombin
particl
express
truncat
version
neu
induc
robust
neuspecif
cell
antineu
igg
respons
singl
administr
veedc
result
regress
larg
establish
tumor
mice
similarli
recombin
sfv
particl
carri
vascular
endotheli
growth
factor
gene
subject
immun
studi
mice
implant
colon
carcinoma
metastas
mammari
carcinoma
prophylact
immun
therapeut
treatment
result
inhibit
tumor
growth
spread
metastas
furthermor
tumor
angiogenesi
significantli
inhibit
coimmun
sfv
particl
express
abrog
immun
respons
tumor
inhibit
contrast
coimmun
particl
elicit
higher
titer
antibodi
gener
superior
surviv
rate
anoth
approach
noncytopath
kun
vlp
express
granulocyt
colonystimul
factor
gcsf
subject
intratumor
administr
mice
implant
aggress
subcutan
colon
carcinoma
melanoma
cure
observ
anim
establish
tumor
regress
associ
induct
anticanc
cell
furthermor
treatment
subcutan
tumor
also
led
regress
lung
metastas
anoth
approach
sfvlacz
rna
evalu
mice
implant
colon
tumor
singl
intramuscular
inject
sfvlacz
rna
elicit
antigenspecif
antibodi
cell
respons
protect
tumor
challeng
achiev
preimmun
anim
therapeut
vaccin
prolong
surviv
mice
preexist
tumor
interestingli
replicon
rna
elicit
significantli
model
antigen
convent
dna
vaccin
vitro
enhanc
vivo
efficaci
correl
caspasedepend
apoptot
cell
death
relat
cervic
cancer
vee
particl
appli
express
human
papilloma
protein
immun
mice
elicit
class
irestrict
cell
respons
prevent
tumor
develop
mice
moreov
vaccin
result
effici
elimin
establish
tumor
tumorbear
anim
anoth
studi
fusion
protein
hpv
express
sfv
vector
contain
translat
enhanc
sfv
capsid
gene
tumorbear
mice
immun
sfvhpv
particl
show
regress
complet
elimin
establish
tumor
moreov
longterm
high
level
cytotox
lymphocyt
activ
observ
last
day
recent
dnabas
sfv
express
hpv
subject
intraderm
administr
follow
electropor
mice
gener
effici
therapeut
antitumor
immun
comparison
convent
dna
vaccin
prevent
tumor
growth
howev
lower
equimolar
dose
sfvhpv
render
immun
mice
tumorfre
combin
therapi
also
appli
sfvhpv
togeth
local
lowdos
irradi
local
lowdos
tumor
irradi
alon
gener
increas
intratumor
cell
howev
combin
sfvhpv
particl
immun
result
intratumor
cell
increas
number
cell
specif
epitop
enhanc
irradi
also
upregul
chemokin
combin
therapi
provid
strong
increas
ratio
antitumor
immun
suppress
cell
therebi
chang
intratumor
immun
balanc
favor
antitumor
activ
furthermor
tripl
treatment
combin
regimen
establish
mgkg
sunitinib
singl
lowdos
gy
tumor
irradi
sfvhpv
immun
treatment
dramat
chang
intratumor
compart
strongli
enhanc
immunotherapeut
antitumor
activ
inhibit
tumor
growth
provid
tumorfre
surviv
mice
tumor
xenograft
relat
lung
cancer
demonstr
dengu
viru
abl
infect
replic
human
primari
lung
epithelium
sever
lung
cancer
cell
line
suscept
cell
line
shown
furthermor
dengu
infect
significantli
increas
express
level
rant
consist
find
dengu
hemorrhag
fever
patient
moreov
sfvegfp
vector
shown
induc
apoptosi
human
nonsmal
cell
lung
carcinoma
cell
inhibit
growth
develop
spheroid
intratumor
sfvegfp
inject
nunu
mice
tumor
xenograft
induc
apoptosi
antitumor
activ
provid
complet
tumor
regress
case
anoth
studi
replicationcompet
sfv
egfp
particl
base
avirul
sfv
strain
local
administ
nude
mice
implant
adenocarcinoma
lung
cell
comparison
second
gener
conditionallyrepl
ad
vector
sfv
egfp
provid
superior
surviv
rate
mice
howev
system
deliveri
abl
elicit
signific
immun
respons
among
rhabdovirus
vsv
particl
express
interferon
subject
intratumor
inject
mice
xenograft
reduc
tumor
growth
furthermor
intratumor
administr
syngen
lung
tumor
grown
flank
aj
mice
provid
prolong
surviv
cure
mice
context
mv
vector
express
slam
rmvslamblind
show
suscept
nine
human
lung
cancer
cell
line
tumor
suppress
detect
mice
lung
xenograft
inject
rmvslamblind
scatter
tumor
mass
grown
lung
target
context
melanoma
sever
preclin
studi
conduct
instanc
yellow
fever
viru
yfv
express
cytotox
lymphocyt
epitop
deriv
chicken
ovalbumin
siinfekl
evalu
mice
immun
result
siinfeklspecif
lymphocyt
induc
protect
challeng
malign
melanoma
cell
moreov
yvf
vaccin
induc
regress
establish
solid
tumor
pulmonari
metastas
addit
alphaviru
vector
appli
melanoma
treatment
vee
particl
express
tyrosinerel
evalu
mous
transplant
melanoma
model
reveal
humor
immun
respons
durabl
antitumor
effect
prolong
surviv
furthermor
particl
combin
either
antagonist
antictl
agonist
antiglucocorticoidinduc
tnf
familyrel
gitr
gene
immunomodulatori
monoclon
antibodi
mab
administr
antigitr
mab
induc
complet
regress
mice
respect
dnabas
coimmun
sfv
vector
express
anoth
sfv
vector
target
survivin
antigen
elicit
effici
humor
cellular
immun
respons
survivin
comparison
immun
sfv
dna
vector
alon
combin
vaccin
show
superior
inhibit
tumor
growth
prolong
surviv
melanoma
mous
model
anoth
studi
vsv
pseudotyp
vsvgp
nonneurotrop
envelop
glycoprotein
lymphocyt
choriomening
viru
lcmv
effect
treatment
malign
glioblastoma
demonstr
effici
infect
kill
human
mous
canin
melanoma
cell
line
moreov
immun
mice
vsvgp
prolong
surviv
xenograft
syngen
mous
model
howev
longterm
tumor
remiss
achiev
mice
vsvgp
oncolyt
viru
also
appli
ovarian
cancer
cell
line
mice
xenograft
oncolyt
activ
detect
ovarian
cancer
cell
line
well
respons
product
type
interferon
similarli
oncolyt
activ
observ
vivo
although
remiss
temporari
howev
combin
therapi
ruxolitinib
enhanc
respons
subcutan
orthotop
xenograft
model
furthermor
alphavirus
subject
preclin
studi
combin
therapi
ovarian
cancer
instanc
combin
sin
topoisomeras
inhibitor
irinotecan
provid
longterm
surviv
sever
combin
immunodefici
scid
mice
aggress
grow
human
ovarian
cancer
contrast
neither
immun
treatment
alon
support
longterm
surviv
anoth
approach
demonstr
immun
vaccinia
viru
vv
ovalbumin
ova
follow
administr
sfvova
vice
versa
enhanc
ovaspecif
cell
immun
respons
tumor
bear
mice
moreov
immun
enhanc
antitumor
effect
murin
ovarian
surfac
epitheli
carcinoma
mosec
tumor
pancreat
cancer
also
target
preclin
studi
context
pancreat
ductal
adenocarcinoma
pda
cell
line
show
superior
oncolyt
abil
vsv
compar
condit
replic
adenoviru
crad
sendai
viru
rsv
moreov
similar
oncolyt
activ
confirm
vivo
moreov
certain
pda
cell
line
hpafii
cell
demonstr
low
suscept
vsv
reveal
resist
could
broken
addit
ruxolitinib
polybren
deaedextran
facilit
treatment
tumor
resist
vsv
therapi
addit
mvslamblind
show
effici
infect
kill
pancreat
cell
line
express
cell
surfac
moreov
intratumor
administr
mvslamblind
gener
substanti
growth
suppress
implant
xenograft
scid
mice
relat
prostat
cancer
selfrepl
rna
vector
appli
studi
sever
anim
model
context
mv
shown
effici
infect
kill
lncap
prostat
cancer
cell
line
appli
express
cea
signific
tumor
growth
delay
prolong
surviv
observ
subcutan
xenograft
model
intratumor
administr
mvcea
anoth
approach
vee
particl
express
prostatespecif
membran
antigen
psma
appli
immun
mice
rabbit
singl
inject
infecti
unit
iu
veepsma
compar
immun
purifi
psma
protein
veebas
approach
provid
stronger
immun
respons
adjuv
psma
protein
furthermor
immunogen
dose
welltoler
vee
particl
also
appli
express
sixtransmembran
epitheli
antigen
prostat
steap
immun
mice
demonstr
specif
cell
respons
prolong
surviv
rate
similarli
immun
vee
particl
express
prostat
stem
cell
antigen
psca
induc
longterm
protect
prostat
cancer
prostat
cancerpron
transgen
adenocarcinoma
mous
prostat
tramp
mice
vaccin
mice
show
surviv
rate
month
age
control
mice
either
succumb
prostat
cancer
present
heavi
tumor
load
final
pseudotyp
vsvgp
particl
evalu
prostat
cancer
mous
model
intratumor
inject
provid
longterm
remiss
interestingli
also
remiss
subcutan
tumor
bone
metastas
intraven
administr
selfrepl
rna
virus
subject
limit
number
clinic
trial
tabl
context
alphavirus
subject
clinic
trial
far
instanc
vee
particl
express
cmv
gb
fusion
protein
appli
random
doubleblind
phase
clinic
trial
cmv
seroneg
individu
intramuscular
subcutan
administr
welltoler
clinic
import
chang
direct
elispot
respons
cmv
antigen
detect
vaccin
subject
moreov
immun
elicit
neutral
antibodi
multifunct
cell
respons
three
cmv
antigen
anoth
studi
healthi
hivneg
volunt
subject
doubleblind
random
placebocontrol
phase
trial
unit
state
south
africa
appli
vee
express
nonmyristoyl
form
gag
subcutan
administr
veegag
welltoler
exhibit
modest
local
immun
respons
low
level
bind
antibodi
cell
respons
although
five
seriou
advers
event
report
none
consid
relat
administ
vaccin
vee
particl
capabl
effici
infect
dc
employ
express
cea
clinic
trial
patient
advanc
cancer
intramuscular
dose
iu
iu
veecea
particl
given
everi
three
week
four
immun
repeat
immun
induc
clinic
relev
ceaspecif
cell
antibodi
respons
antibodydepend
cellular
toxic
tumor
cell
human
colorect
cancer
metastas
mediat
ceaspecif
antibodi
moreov
longer
overal
surviv
observ
patient
ceaspecif
cell
respons
propagationdefect
vee
particl
express
psma
also
subject
phase
clinic
trial
patient
castrat
resist
metastat
prostat
cancer
crpc
five
dose
either
iu
iu
veepsma
administ
patient
crpc
metastat
bone
vaccin
welltoler
dose
although
weak
psmaspecif
signal
detect
although
neither
clinic
benefit
robust
immun
respons
achiev
elicit
neutral
antibodi
suggest
dose
suboptim
anoth
approach
sfv
particl
express
encapsul
liposom
provid
passiv
tumor
target
protect
host
immun
recognit
intraven
administ
melanoma
kidney
carcinoma
patient
phase
clinic
trial
patient
receiv
show
transient
five
day
increas
plasma
level
encapsul
enhanc
tumor
target
prevent
host
immun
recognit
repeat
inject
furthermor
toxic
relat
treatment
maximum
toler
dose
mtd
determin
particl
per
sever
vsvbase
clinic
trial
conduct
two
placebocontrol
doubleblind
doseescal
phase
trial
perform
recombin
vsv
particl
express
glycoprotein
zair
strain
ebola
viru
total
volunt
receiv
one
three
dose
pfu
vsvzebov
assess
safeti
immunogen
vaccin
advers
event
injectionsit
pain
fatigu
myalgia
headach
occur
lower
titer
observ
day
dose
pfu
comparison
two
dose
furthermor
second
dose
day
significantli
increas
antibodi
titer
day
effect
disappear
month
anoth
random
doserang
observerblind
placebocontrol
phase
trial
particip
receiv
attenu
vaccin
seriou
advers
event
encount
vaccine
develop
immun
respons
compar
across
dose
appli
sustain
igg
titer
detect
throughout
whole
studi
day
furthermor
anoth
phase
studi
vsvzebov
show
good
toler
vaccinerel
advers
event
superior
cellular
immun
respons
stronger
interlock
cytokin
network
immun
highest
dose
pfu
geneva
phase
iii
dosefind
placebocontrol
doubleblind
studi
vsvzebov
dose
reduc
pfu
compar
previou
dose
pfu
lower
dose
improv
toler
decreas
antibodi
respons
moreov
prevent
vaccinerel
arthriti
dermat
vascul
random
placebocontrol
phase
iii
trial
conduct
adult
chimpanze
recombin
vsv
vaccin
liberia
advers
event
includ
injectionsit
reaction
headach
fever
fatigu
occur
significantli
frequent
individu
receiv
activ
vaccin
compar
placebo
antibodi
respons
detect
subject
group
respect
compar
placebo
group
one
month
vaccin
month
percentag
group
respect
placebo
group
anoth
phase
iii
trial
conduct
guinea
openlabel
clusterrandom
ring
vaccin
studi
suspect
case
ebola
viru
diseas
ebv
total
number
individu
includ
person
assign
immedi
vaccin
rvsvzebov
person
assign
delay
vaccin
case
ebv
detect
immedi
vaccin
group
day
wherea
case
ebv
regist
delay
vaccin
group
new
case
ebv
diagnos
either
group
overal
rvsvzebov
vaccin
confirm
safe
show
promis
highli
effici
prevent
ebv
anoth
phase
iii
studi
conduct
guinea
sierra
leon
appli
singl
intramuscular
vaccin
pfu
rvsvzebov
random
trial
individu
immedi
vaccin
person
vaccin
delay
day
random
vaccin
individu
follow
day
offer
substanti
protect
ebv
case
ebv
discov
day
vaccin
moreov
individuallycontrol
phase
iiiii
trial
conduct
health
care
frontlin
worker
five
ebv
affect
district
sierra
leon
singl
intramuscular
dose
administ
enrol
week
enrol
outcom
indic
ebv
case
vaccinerel
seriou
advers
event
report
final
random
doubleblind
multicent
phase
iii
trial
conduct
unit
state
spain
canada
vaccin
taken
place
dose
pfu
pfu
placebo
assess
safeti
immunogen
vaccin
gener
welltoler
although
system
advers
event
occur
comparison
placebo
vaccinerel
sever
advers
event
death
report
overal
result
confirm
safeti
vaccin
ebv
risk
popul
mvedm
vaccin
strain
test
clinic
trial
breast
ovarian
head
neck
cancer
glioblastoma
myeloma
context
openlabel
nonrandom
doseescal
phase
trial
conduct
unmodifi
vaccin
strain
mvedm
zagreb
mvez
patient
cutan
cell
lymphoma
intratumor
inject
mvez
day
preced
subcutan
inject
h
prior
mvez
maximum
toler
dose
defin
complet
regress
ctcl
lesion
observ
one
patient
partial
regress
observ
patient
relat
recombin
mv
phase
trial
conduct
patient
advanc
ovarian
cancer
intraperiton
inject
mvcea
administr
mvcea
dose
confirm
doselimit
toxic
best
object
respons
compris
stabl
diseas
patient
median
durat
day
rang
day
individu
vaccin
higher
dose
level
accomplish
stabl
diseas
wherea
five
patient
vaccin
achiev
mvcea
also
plan
phase
clinic
trial
patient
recurr
glioblastoma
multiform
studi
aim
treatment
start
dose
mvcea
escal
maximum
dose
level
one
group
patient
receiv
direct
inject
resect
caviti
group
mvcea
administ
recurr
tumor
far
three
patient
receiv
three
patient
resect
caviti
show
doselimit
toxic
oncolyt
mv
vector
express
human
sodium
iodid
symport
ni
subject
phase
trial
patient
relaps
refractori
myeloma
receiv
intraven
mvni
cyclophosphamid
two
day
prior
mvni
treatment
initi
doseescal
studi
reveal
mtd
reach
therefor
dose
test
latter
dose
plan
use
phase
ii
trial
complet
respons
observ
one
patient
treat
respons
persist
month
isol
relaps
occur
skull
without
recurr
marrow
involv
irradi
lesion
result
patient
remain
diseasefre
addit
month
anoth
patient
subject
soften
shrink
extramedullari
plasmacytoma
back
thigh
summari
numer
preclin
clinic
studi
confirm
feasibl
approach
appli
selfrepl
rna
virus
prevent
therapeut
use
variou
diseas
tabl
tabl
tabl
context
immun
selfrepl
rna
virus
gener
strong
immun
respons
mani
case
provid
protect
challeng
lethal
dose
infecti
agent
moreov
administr
selfrepl
rna
viral
vector
express
anticanc
toxic
andor
immunostimulatori
gene
demonstr
tumor
growth
inhibit
regress
even
complet
tumor
erad
support
signific
prolong
surviv
profil
immun
also
provid
prophylact
protect
challeng
tumor
cell
anim
model
one
interest
aspect
appli
selfrepl
rna
virus
compris
possibl
use
rna
replicon
replicationdefici
compet
particl
layer
dnarna
vector
provid
certain
flexibl
choos
mean
deliveri
vehicl
specif
applic
moreov
sever
attempt
made
engin
vector
specif
target
replic
kill
tumor
cell
one
approach
appli
oncolyt
viral
vector
provid
specif
kill
tumor
cell
without
affect
normal
cell
anoth
approach
recombin
sfv
particl
encapsul
liposom
provid
passiv
target
tumor
protect
recognit
host
immun
system
moreov
limit
vector
use
due
host
immun
respons
address
engin
polymerco
mvnpl
vector
base
mv
edmonston
strain
n
p
l
gene
wildtyp
mv
strain
polymerco
mvnpl
show
superior
oncolyt
activ
vitro
compar
nake
mvnpl
moreov
polymerco
mvnpl
provid
higher
complementdepend
cytotox
antitumor
activ
nake
viru
mice
context
optim
immun
respons
specif
target
dc
proven
use
approach
demonstr
enhanc
immun
respons
vee
vector
transduc
dc
recent
deliveri
dc
translat
replicon
rna
classic
swine
fever
viru
csfv
encod
influenza
viru
np
belong
flavivirus
improv
lipid
formul
demonstr
vitro
vivo
induc
immun
respons
influenza
np
moreov
potenti
enhanc
therapeut
efficaci
address
variou
applic
combin
therapi
instanc
tripl
treatment
combin
sunitinib
lowdos
irradi
sfvhpv
particl
render
mice
tumorfre
similarli
combin
vsv
immun
ruxolitinib
administr
enhanc
respons
subcutan
orthotrop
xenograft
model
furthermor
ruxolitinib
polybren
deaedextran
render
vsvresist
cell
suscept
aid
vsvbase
therapi
although
rel
small
number
clinic
trial
conduct
selfrepl
rna
virus
promis
result
especi
sever
phase
iii
trial
mvbase
vaccin
ebv
provid
good
safeti
profil
protect
alphaviru
vector
subject
clinic
trial
infecti
diseas
far
elicit
immun
respons
rel
modest
least
extent
relat
lack
dose
optim
context
use
selfrepl
rna
virus
cancer
therapi
less
progress
seen
compar
infecti
diseas
howev
veecea
particl
show
prolong
surviv
phase
trial
pancreat
cancer
moreov
promis
result
obtain
liposom
encapsul
sfv
particl
termin
ill
melanoma
kidney
carcinoma
patient
also
mv
vector
shown
regress
lymphoma
lesion
stabl
diseas
treatment
ovarian
cancer
complet
respons
one
myeloma
patient
one
import
issu
relat
util
deliveri
system
safeti
first
phase
essenti
provid
high
safeti
standard
laboratori
research
largescal
product
ensur
protect
personnel
relat
selfrepl
rna
virus
special
attent
paid
engin
helper
viru
vector
use
viru
prepar
laboratori
largescal
initi
introduct
point
mutat
precursor
sfv
envelop
gene
render
gener
recombin
particl
condit
infecti
requir
addit
activ
step
second
gener
vector
reduc
gener
replicationcompet
sfv
particl
undetect
level
introduct
split
helper
system
sfv
sin
capsid
envelop
protein
place
separ
plasmid
gener
hightit
particl
elimin
product
recombinantprofici
alphaviru
particl
moreov
selfrepl
rna
alphavirus
flavivirus
mv
classifi
laboratori
biosafeti
level
although
gene
interest
express
vector
might
impact
level
relat
toxic
advers
event
observ
patient
subject
viral
inject
vee
particl
welltoler
show
local
reactogen
clinic
import
chang
howev
although
five
seriou
advers
event
record
phase
studi
healthi
hivuninfect
individu
none
consid
relat
vaccin
advers
event
relat
immun
ebola
patient
vsv
vector
compris
pain
inject
site
fatigu
myalgia
headach
similarli
immun
healthi
volunt
vaccin
show
mild
moder
selflimit
advers
event
injectionsit
pain
headach
followup
period
relat
toxic
issu
phase
studi
crpc
patient
demonstr
veepsma
administr
welltoler
toxic
observ
likewis
welltoler
ovarian
cancer
patient
show
doselimit
toxic
mvcea
interestingli
phase
trial
pancreat
cancer
patient
show
feasibl
repeat
inject
moreov
liposomeencapsul
particl
could
repeatedli
administ
kidney
carcinoma
melanoma
patient
without
demonstr
toxic
viru
liposomerel
immun
respons
look
futur
continu
vector
develop
aim
deliveri
safeti
improv
certainli
support
progress
therapeut
applic
selfrepl
rna
viral
vector
moreov
dose
optim
studi
especi
clinic
level
need
conduct
vaccin
develop
gene
therapi
approach
taken
giant
leap
recent
classic
approach
pioneer
effort
use
viral
vector
nucleic
acid
attract
featur
selfrepl
rna
virus
relat
easi
viru
product
broad
host
rang
high
safeti
level
due
risk
chromosom
integr
target
dc
importantli
extrem
rna
replic
cytoplasm
support
high
level
transgen
express
basi
gener
strong
immun
respons
today
rnabas
deliveri
provid
attract
approach
especi
combin
either
polym
liposomebas
encapsul
strategi
